Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioXcel Therapeutics (BTAI) Equity Average (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Equity Average data on record, last reported at -$98.3 million in Q3 2025.

  • For Q3 2025, Equity Average fell 22.92% year-over-year to -$98.3 million; the TTM value through Sep 2025 reached -$98.3 million, down 22.92%, while the annual FY2024 figure was -$74.8 million, 838.19% down from the prior year.
  • Equity Average reached -$98.3 million in Q3 2025 per BTAI's latest filing, up from -$98.9 million in the prior quarter.
  • Across five years, Equity Average topped out at $179.1 million in Q2 2022 and bottomed at -$98.9 million in Q2 2025.
  • Average Equity Average over 4 years is -$10.1 million, with a median of -$56.5 million recorded in 2023.
  • Peak YoY movement for Equity Average: tumbled 360.32% in 2024, then decreased 22.92% in 2025.
  • A 4-year view of Equity Average shows it stood at $101.9 million in 2022, then tumbled by 147.66% to -$48.6 million in 2023, then tumbled by 84.04% to -$89.4 million in 2024, then dropped by 9.99% to -$98.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were -$98.3 million in Q3 2025, -$98.9 million in Q2 2025, and -$91.6 million in Q1 2025.